Imugene Ltd (ASX:IMU, OTC:IUGNF, FRA:ILA) will present updated clinical data on its lead cell therapy program at one of the world’s largest healthcare investment forums next week, as the company ...

Anuj Gupta is CEO and Co-founder of Eucloid Data Solutions and advisor to CDOs and CIOs of Fortune-100 organizations and market leaders. Enterprise data platforms seem to have moved faster in 2025 ...

Rand Fishkin just published the most important piece of primary research the AI visibility industry has seen so far. His conclusion – that AI tools produce wildly inconsistent brand recommendation ...

Carolyn Gusoff has covered some of the most high profile news stories in the New York City area and is best known as a trusted, tenacious, consistent and caring voice of Long Island's concerns. A ...

With community opposition growing, data center backers are going on a full-scale public relations blitz. Around Christmas in Virginia, which boasts the highest concentration of data centers in the ...

If you build engines, tune cars, or even just like mashing your foot on the throttle with conviction, you’ve probably heard the term “wideband O2 sensor” being thrown around at the track, dyno ...

Some users have reported that when they open MS Outlook, they receive an error message that Outlook is using an old copy of your Outlook data file (.ost). For some ...

Growing customer use of artificial intelligence (AI) alongside the continued draw of live sports and major gaming releases has resulted in record levels of data consumption across the networks of ...

Virgin Media O2 has released its 2025 Year in Review, revealing record levels of data consumption in the UK, including an 8 per cent rise in broadband usage and an 18 per cent rise in mobile traffic.

ORLANDO, Fla.—The leader of Gilead Sciences' Kite Pharma is sure that anito-cel, the biotech’s next-generation multiple myeloma CAR-T challenger to Carvykti, is ready for prime time—and that the ...

– 96% Overall Response Rate, 74% Stringent Complete Response/Complete Response, and 95% Minimal Residual Disease Negativity Observed at a Median 15.9-months of Follow-up, with Responses Continuing to ...